Limits...
Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.

Han L, Shang YM, Song YP, Gao QL - J Immunol Res (2016)

Bottom Line: Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%.No serious toxicity was associated with R-CIK cell infusion.In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.

ABSTRACT
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

No MeSH data available.


Related in: MedlinePlus

Cytotoxicity of OKT-CIK and R-CIK cells against K562 cells. Both OKT-CIK and R-CIK cells could kill K562 cells at different effect or target ratio, but there was no statistical difference between the two groups. P > 0.05, n = 5.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4940556&req=5

fig4: Cytotoxicity of OKT-CIK and R-CIK cells against K562 cells. Both OKT-CIK and R-CIK cells could kill K562 cells at different effect or target ratio, but there was no statistical difference between the two groups. P > 0.05, n = 5.

Mentions: The OKT-CIK and R-CIK cells were tested for cytotoxicity against the K562 tumor cells, measured by CFSE/PI double staining and flow cytometry analysis. As shown in Figure 4, both OKT-CIK and R-CIK cells could kill K562 cells at different effector/target ratio, but there was no statistical difference between the two group cells (P > 0.05).


Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.

Han L, Shang YM, Song YP, Gao QL - J Immunol Res (2016)

Cytotoxicity of OKT-CIK and R-CIK cells against K562 cells. Both OKT-CIK and R-CIK cells could kill K562 cells at different effect or target ratio, but there was no statistical difference between the two groups. P > 0.05, n = 5.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4940556&req=5

fig4: Cytotoxicity of OKT-CIK and R-CIK cells against K562 cells. Both OKT-CIK and R-CIK cells could kill K562 cells at different effect or target ratio, but there was no statistical difference between the two groups. P > 0.05, n = 5.
Mentions: The OKT-CIK and R-CIK cells were tested for cytotoxicity against the K562 tumor cells, measured by CFSE/PI double staining and flow cytometry analysis. As shown in Figure 4, both OKT-CIK and R-CIK cells could kill K562 cells at different effector/target ratio, but there was no statistical difference between the two group cells (P > 0.05).

Bottom Line: Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%.No serious toxicity was associated with R-CIK cell infusion.In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.

ABSTRACT
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

No MeSH data available.


Related in: MedlinePlus